VERTEX PHARMACEUTIC (VX1 BE) stock market data APIs
€400.6054
0(0%)
as of July 15, 2025
Try our APIs with
free plan!
VERTEX PHARMACEUTIC Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for VX1.BE.
Prev. Close
400.6054
Open
400.6054
High
400.6054
Low
400.6054
52 wk Range
372.95-482
Market Cap
46 841 M
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get VERTEX PHARMACEUTIC data using free add-ons & libraries
Get VERTEX PHARMACEUTIC Fundamental Data
VERTEX PHARMACEUTIC Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
VERTEX PHARMACEUTIC News
New
Exploring 3 High Growth Tech Stocks In The US Market
As the U.S. stock market experiences mixed movements with major indexes reaching record highs amidst inflation data and earnings reports, the tech sector stands out with notable rallies spurred by com...
Vertex Pharmaceuticals (VRTX) Secures NHS England Agreement For Next-In-Class Cystic Fibrosis Treatment
Vertex Pharmaceuticals experienced a 4% price increase over the past month, coinciding with crucial developments in their portfolio. The recent advancement with NHS England's reimbursement agreement f...
EU Commission Approves Vertex Pharmaceutical’s (VRTX) Cystic Fibrosis Treatment
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the European Commission approved the company’s new cystic fibrosis treatment, ALYF...
Vertex Pharmaceuticals And 2 Other Stocks That May Be Trading Below Their Estimated Value
Over the last 7 days, the United States market has remained flat, yet it has experienced an 11% increase over the past year with earnings projected to grow by 15% annually. In this environment, identi...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
